title: Nucleoside analogue delivery systems in cancer therapy.
abstract: Nucleoside analogues (NAs) are important agents in the treatment of hematological malignancies. They are prodrugs that require activation by phosphorylation. Their rapid catabolism, cell resistance and overdistribution in the body jeopardize nucleoside analogue chemotherapy. Accordingly, therapeutic doses of NAs are particularly high and regularly have to be increased, resulting in severe toxicity and narrow therapeutic index. The major challenge is to concentrate the drug at the tumour site, avoiding its distribution to normal tissues. New drug carriers and biomaterials are being developed to overcome some of these obstacles. This review highlights novel NA delivery systems and discusses new technologies that could improve NA cancer therapy.
authors: School of Pharmacy, Université Lyon 1-ESCPE - UMR 5007, Laboratoire d'Automatique et de Génie des Procédés, Bât. 308 G, 43, Bd du 11 Novembre 1918, 69622 Villeurbanne Cedex, France.
authors: Roudayna
authors: R
authors: Diab
authors: Ghania
authors: G
authors: Degobert
authors: Misara
authors: M
authors: Hamoudeh
authors: Charles
authors: C
authors: Dumontet
authors: Hatem
authors: H
authors: Fessi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D009705:Nucleosides / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D011355:Prodrugs; D013678:Technology, Pharmaceutical
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D009705:Nucleosides; D011355:Prodrugs